Beacon Pointe Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
EIG
Beacon Pointe Advisors's DGX Position: Q2 2026 in Review
Beacon Pointe Advisors reduced its Quest Diagnostics (DGX) stake by 16% in Q2 2026, selling an estimated $122K and leaving 3,169 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #1203.
Beacon Pointe Advisors first reported a position in DGX in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.41M in Q1 2022. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Beacon Pointe Advisors held 3,169 shares of Quest Diagnostics worth $671K as of Q2 2026.
- Beacon Pointe Advisors sold 622 Quest Diagnostics shares in Q2 2026, an estimated $122K.
- Quest Diagnostics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1203 holding.
- Beacon Pointe Advisors first reported a position in Quest Diagnostics in Q2 2021 and has held it in 20 quarters since.
- Beacon Pointe Advisors's Quest Diagnostics position peaked at $1.41M in Q1 2022.
- 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.